The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. “As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Headline
A Centers for Disease Control and Prevention report highlights differences in substance use among U.S. high school students. The report, which combined data…
Headline
The Department of Health and Human Services Office for Civil Rights released new guidance on statutory and regulatory requirements under 42 CFR Part 2, which…
Headline
The Health Resources and Services Administration announced Sept. 25 that it awarded $89.3 million in grants to expand access to substance use disorder…
Headline
The Substance Abuse and Mental Health Services Administration Sept. 25 announced that it awarded $247.9 million in grants for services expanding access to…
Headline
The Substance Abuse and Mental Health Services Administration announced Sept. 18 that it awarded $42.3 million in grants to states and territories to support…
Blog
To reduce suicide in the healthcare workforce, hospitals and health systems must create an environment where workers feel safe asking for help.By Susan…